The massive rise of patient advocacy in the US has led to an aggressive, if inadvertent, contest between disease-specific lobbyists. Advocacy groups say they're just trying to get taxpayer-backed research dollars distributed equitably according to public health need and they deny any outright competition with one another. But with research budgets shrinking, advocacy becomes a zero-sum game. Some scientists worry that pitting one disease against another threatens the leadership of government funding bodies—not to mention the basic research enterprise. Virginia Hughes reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Journal
Get full journal access for 1 year
114,72 €
only 9,56 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Marshall, E. Science 276, 344–346 (1997).
Best, R.K. Am. Sociol. Rev. 77, 780–803 (2012).
Gillum, L.A. et al. PLoS ONE 6, e16837 (2011).
Gross, C.P., Anderson, G.F. & Powe N.R. N. Engl. J. Med. 340, 1881–1887 (1999).
Sampat, B.N. Buterbaugh, K. & Perl, M. Milbank Q. 91, 163–185 (2013).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, V. The disease olympics. Nat Med 19, 257–260 (2013). https://doi.org/10.1038/nm0313-257
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0313-257